ScinoPharm Taiwan Ltd (1789):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ScinoPharm Taiwan Ltd (1789) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9830
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ScinoPharm Taiwan Ltd (ScinoPharm) provides process research and development (R&D) and active pharmaceutical ingredient (API) manufacturing services to the pharmaceutical industry. It services include custom synthesis for early phase pharmaceutical activities, brand companies and APIs for the generic industry. ScinoPharm also provides contract research and manufacturing services (CRAM) services including chemistry skill, analytical and regulatory services, chemical process development, clinical drug substances, exploratory process research and consulting services. The company has research and manufacturing facilities in Taiwan and China. ScinoPharm is headquartered in Tainan, Taiwan.

ScinoPharm Taiwan Ltd (1789) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Baxter International Enters into Agreement with ScinoPharm Taiwan 10
ScinoPharm Enters into Agreement with CVie Therapeutics 11
ScinoPharm Enters into R&D Agreement with Nanjing King-friend Biochemical Pharma 12
ScinoPharm Enters Into Co-Development Agreement With Lee’s Pharma For Fondaparinux Sodium 13
ScinoPharm Announces Co-Development Agreement With Lee’s Pharma For Travoprost And Bimatoprost 14
Genovate Biotech Enters Into Co-Development Agreement With ScinoPharm Taiwan For Livepro 15
ScinoPharm Taiwan And Coland Enter Into Agreement To Develop Generic Oncological Drugs 16
ScinoPharm Taiwan Enters Into Joint Venture Agreement With Foresee Pharma For New Oncology Drugs 17
ScinoPharm Taiwan Ltd – Key Competitors 18
ScinoPharm Taiwan Ltd – Key Employees 19
ScinoPharm Taiwan Ltd – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Feb 23, 2018: ScinoPharm Reports Financial Performance for 2017 21
Feb 15, 2017: ScinoPharm Reports Financial Performance for 2016 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ScinoPharm Taiwan Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Baxter International Enters into Agreement with ScinoPharm Taiwan 10
ScinoPharm Enters into Agreement with CVie Therapeutics 11
ScinoPharm Enters into R&D Agreement with Nanjing King-friend Biochemical Pharma 12
ScinoPharm Enters Into Co-Development Agreement With Lee’s Pharma For Fondaparinux Sodium 13
ScinoPharm Announces Co-Development Agreement With Lee’s Pharma For Travoprost And Bimatoprost 14
Genovate Biotech Enters Into Co-Development Agreement With ScinoPharm Taiwan For Livepro 15
ScinoPharm Taiwan And Coland Enter Into Agreement To Develop Generic Oncological Drugs 16
ScinoPharm Taiwan Enters Into Joint Venture Agreement With Foresee Pharma For New Oncology Drugs 17
ScinoPharm Taiwan Ltd, Key Competitors 18
ScinoPharm Taiwan Ltd, Key Employees 19
ScinoPharm Taiwan Ltd, Other Locations 20
ScinoPharm Taiwan Ltd, Subsidiaries 20

List of Figures
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ScinoPharm Taiwan Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[ScinoPharm Taiwan Ltd (1789):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ora Gold Ltd (THX):企業の財務・戦略的SWOT分析
    Summary Ora Gold Ltd (Ora Gold) is a mining and mineral exploration company. The company acquires, explores and develops lead, zinc, silver, nickel, graphite, copper, gold and uranium prospects in Western Australia and the Northern Territory. Its projects include Red Bore Copper-Gold Project, Garden …
  • MS&AD Insurance Group Holdings, Inc.:企業のM&A・事業提携・投資動向
    MS&AD Insurance Group Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's MS&AD Insurance Group Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • Lightbridge Corporation (LTBR)-エネルギー分野:企業M&A・提携分析
    Summary Lightbridge Corporation (Lightbridge) is a nuclear fuel technology company, which develops thorium based nuclear fuel technologies for nuclear reactor systems, that increases the power output of commercial reactors; generates nuclear energy and the amount of nuclear waste on a per-megawatt-h …
  • SimCorp AS (SIM):企業の財務・戦略的SWOT分析
    SimCorp AS (SIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Isagenix International LLC:企業の戦略的SWOT分析
    Isagenix International LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Tokyo Electron Limited:企業の戦略・SWOT・財務分析
    Tokyo Electron Limited - Strategy, SWOT and Corporate Finance Report Summary Tokyo Electron Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Upstream Medical Technologies Ltd:企業の製品パイプライン分析2018
    Summary Upstream Medical Technologies Ltd (UMT) is a biomarker based testing developer that markets novel biomarkers for cardiac diagnosis. The company offers patented pipeline of products such as BNP-sp, used for diagnoses of unstable angina, CVD, ACS, and others. It provides pipe line product such …
  • Halozyme Therapeutics Inc (HALO):企業の財務・戦略的SWOT分析
    Halozyme Therapeutics Inc (HALO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Molecular Health GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Molecular Health GmbH (Molecular Health) is a biomedical company that designs, develops, manufactures and commercializes software systems which performs integrated analysis of clinical and genomic patient data to support treatment decisions and provide related services. The company offers Mo …
  • Huawei Investment & Holding Co., Ltd.:企業の戦略・SWOT・財務情報
    Huawei Investment & Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Huawei Investment & Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • CESC Ltd (CESC):企業の財務・戦略的SWOT分析
    CESC Ltd (CESC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • RPG Cables Limited:企業の戦略・SWOT・財務情報
    RPG Cables Limited - Strategy, SWOT and Corporate Finance Report Summary RPG Cables Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • McCarthy & Stone Plc:企業の戦略・SWOT・財務分析
    McCarthy & Stone Plc - Strategy, SWOT and Corporate Finance Report Summary McCarthy & Stone Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Religare Enterprises Limited:企業のM&A・事業提携・投資動向
    Religare Enterprises Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Religare Enterprises Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Givaudan SA:戦略・SWOT・企業財務分析
    Givaudan SA - Strategy, SWOT and Corporate Finance Report Summary Givaudan SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • AUDI AG:企業の戦略・SWOT・財務分析
    AUDI AG - Strategy, SWOT and Corporate Finance Report Summary AUDI AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • HomeServe plc (HSV):企業の財務・戦略的SWOT分析
    HomeServe plc (HSV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Oncternal Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Oncternal Therapeutics Inc (Oncternal), formerly Tokalas, Inc., is a clinical-stage oncology company which focuses on the development of therapies for rare and common cancers. Its pipeline compound portfolio includes cirmtuzumab and TK216. The company’s pipeline compounds are primarily focus …
  • The Walsh Group:企業の戦略・SWOT・財務分析
    The Walsh Group - Strategy, SWOT and Corporate Finance Report Summary The Walsh Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • VisionQuest Biomedical LLC:製品パイプライン分析
    Summary VisionQuest Biomedical LLC (VisionQuest) is a medical device company that develops medical imaging tools for the diagnostic services. The company’s products include eyestar, DR-RACS, and neurotherm. Its eyestar product is a total eye disease screening program package; DR-RACS is an automated …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆